NPC1 and Alzheimer disease: Therefore, since miglustat can easily cross the blood–brain barrier and is well tolerated by humans, we speculated its possible use as a disease‐modifying therapy for AD, especially in AD patients harboring a heterozygous NPC1 mutation.